日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data

利用临床前和临床数据，采用 mPBPK/RO 模型选择 DuoBody®-CD40x4-1BB (GEN1042/BNT312) 的剂量

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.3677
Bajaj, Gaurav; Shchelokov, Dmitry; Demin, Oleg Jr; Adams, Homer C 3rd; Feng, Yan; Gibiansky, Leonid; van der Lee, Saskia; Johri, Anandhi; Belete, Merzu; Muik, Alexander; Panorchan, Porntula; Türeci, Özlem; Sahin, Uğur; Ahmadi, Tahamtan; Gupta, Manish; Demin, Oleg; Thalhauser, Craig
T细胞
CD4
CD40
发表日期：2025
文献求助 收藏

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies

定量系统药理学模型预测布鲁顿酪氨酸激酶抑制剂在B细胞恶性肿瘤患者中的靶点占有率

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.13307
Demin, Oleg Jr; Ou, Ying; Kolesova, Galina; Shchelokov, Dmitry; Stepanov, Alexander; Musatova, Veronika; Sahasranaman, Sri; Zhao, Yating; Liu, Xiangyu; Tang, Zhiyu; Hanley, William D
B细胞
肿瘤
肿瘤免疫
信号转导
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study

基于定量系统药理学的受体占有率评估和解释：纳武利尤单抗案例研究

期刊:MAbs
影响因子:7.3
doi:10.1080/19420862.2022.2156317
Shchelokov, Dmitry; Demin, Oleg Jr
信号转导
发表日期：2023
文献求助 收藏

Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta

利用淀粉样β蛋白积累和分布的转化纵向模型研究淀粉样蛋白病理的进展及其治疗

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12249
Karelina, Tatiana; Demin, Oleg Jr; Demin, Oleg; Duvvuri, Sridhar; Nicholas, Timothy
发表日期：2017
文献求助 收藏